Fifth Eye joins CancerX 2025 Accelerator
CancerX shared a post on LinkedIn:
“With septic shock alone accounting for 270,000 deaths and $38 billion in costs annually in the US, Fifth Eye Inc.’s technology represents the kind of transformative digital innovation in healthcare that CancerX and our champions are committed to advancing.
Their groundbreaking technology is the first-ever FDA-cleared indicator of hemodynamic compensation and predictor of hemodynamic instability.
What makes this innovation particularly remarkable is its ability to accurately alert medical teams to impending shock up to 24 hours ahead of traditional vital sign indicators.
For cancer patients, who are often immunocompromised and at higher risk for complications like septic shock, this early warning system could be life-saving – We’re thrilled to have Fifth Eye in the CancerX 2025 Accelerator!
We look forward to supporting their mission to detect critical conditions earlier and save more lives!”
More posts featuring CancerX.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023